Current stock page

Catalysts

MDGL Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

MDGLMadrigal Pharmaceuticals, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 6/10
$427.39+$2.18 (+0.51%)

Latest quote

  • Momentum
    40
  • Value
    66
  • Quality
    67
  • Risk resilience
    63
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 18, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 57/100

Momentum 40/100 and sentiment — before the next covered event.

Recent coverage
4 articles

Updated Nov 15, 2026 · Sentiment 44.16%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 40/100AIQ Edge 6/10 Above Peers
Beat rate
75%
6 of 8 reported periods
Average surprise
-779.5%
Across covered historical reports
Latest result
+312.0%
Nov 3, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 3, 2026—-$0.86$1.83+312.0%$404.17M$431.27M
Jul 30, 2026—-$2.68-$1.99+25.7%$352.13M$364.3M
May 6, 2026—-$3.61-$3.25+10.0%$301.05M$311.34M
Feb 19, 2026—$0.04-$2.57-6525.0%$312.51M$321.1M
Nov 4, 2025—-$2.04-$5.08-149.4%$244.96M$287.27M
Aug 5, 2025—-$3.48-$1.90+45.4%$243.47M$212.8M
May 1, 2025—-$3.62-$3.32+8.3%$158.93M$137.25M
Feb 26, 2025—-$4.32-$2.71+37.3%$97.81M$103.32M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
18
Buy
1
Hold
12-month analyst target
$660.50
+54.54% versus current price
Based on 19 analyst observations. Targets are estimates, not predictions.
Low target
$533.00
+24.71% vs latest price
Average target
$660.50
+54.54% vs latest price
High target
$735.00
+71.97% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 18, 2027

Next known earnings or reporting date.

EPS estimate$1.43

Current analyst expectation for the upcoming report.

Revenue estimate$477.02M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score40

Where event reaction would show up first.

AIQ score57/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
19
Average target
$660.50
Target upside
54.54%
Target range
$533.00 - $735.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
0
Negative
0
seekingalpha.com · Nov 4, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call Transcript

Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call November 3, 2026 8:00 AM ESTCompany ParticipantsTina Ventura - Chief Investor Relations...

gurufocus.com · Sep 24, 2026

MDGL Reinstated by Goldman Sachs -- Price Target Announced at $704

On October 03, 2023, Goldman Sachs reinstated Madrigal Pharmaceuticals (MDGL) with a "Buy" rating. The new price target is set at $704.00. Current ma

gurufocus.com · Sep 24, 2026

Goldman Sachs Reinitiates Coverage on Madrigal Pharmaceuticals (MDGL) with Buy Rating and $704 Price Target

On September 24, 2026, Goldman Sachs restarted its analysis of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL), assigning a Buy rating and setting a price target of

gurufocus.com · Sep 2, 2026

Madrigal Pharmaceuticals (MDGL) Leads Healthcare CapEx Growth Amid Elevated Price-to-Sales Valuation

On September 02, 2026, as the second-quarter earnings season wrapped up, Madrigal Pharmaceuticals, Inc. (MDGL) stood out with a remarkable 779.77% year-over-yea

Open full news and sentiment

MDGL Catalysts FAQ

What are the next catalysts for MDGL stock?

MDGL's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move MDGL stock?

Upcoming events that could move MDGL include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could MDGL's next earnings report affect the stock?

MDGL's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive MDGL stock higher?

MDGL could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt MDGL stock?

MDGL could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.